Karyopharm Therapeutics (KPTI) Projected to Post Quarterly Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) is projected to issue its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($3.67) per share and revenue of $39.5620 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:00 AM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million during the quarter, compared to analyst estimates of $37.92 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Karyopharm Therapeutics Stock Down 2.9%

Shares of KPTI stock opened at $5.79 on Friday. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $16.95. The stock has a market cap of $50.20 million, a P/E ratio of -0.40 and a beta of 0.34. The business has a fifty day simple moving average of $6.36 and a 200-day simple moving average of $5.37.

Analysts Set New Price Targets

A number of analysts recently commented on KPTI shares. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th. Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. HC Wainwright upgraded Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Monday, October 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.20.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $56,000. Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. Finally, Bank of America Corp DE lifted its stake in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares in the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).